Effect of treatment with nebivolol on parameters of oxidative stress in type 2 diabetics with mild to moderate hypertension

Journal of Clinical Pharmacy and Therapeutics
P PeterF Dunne

Abstract

The aim of this study was to examine the effect of the cadioselective B(1)-adrenoceptor blocker nebivolol on glycaemic control, lipid profile and markers of oxidative stress in patients with type 2 diabetes over a 6-month period. Twenty-six patients with mild to moderate hypertension (140-160 mmHg systolic, 90-105 mmHg diastolic) confirmed on 24-h blood pressure monitoring, were treated with nebivolol 5 mg daily for 6 months. Total serum cholesterol, triglycerides, high-density lipoprotein (HDL) cholesterol and low-density lipoprotein (LDL) subfractions, lipid hydroperoxides (LHPs) and total antioxidant capacity (TAC) were measured before and after 6 months of treatment. Nebivolol, as expected, reduced mean daytime systolic and diastolic pressures on ambulatory monitoring (149 +/- 9 to 140 +/- 13 mmHg, P = 0.02 and 84 +/- 7 to 77 +/- 9 mmHg, P < 0.001). There were no significant changes in serum cholesterol or triglycerides following treatment but a significant increase in HDL cholesterol was noted (1.12 +/- 0.19 to 1.25 +/- 0.36 mmol/L, P = 0.008). Patients showed a highly significant reduction in TAC from 501 +/- 57 to 422 +/- 29 trolox equivalent (P < 0.001). Baseline LHPs were very high and showed no significant change over...Continue Reading

References

Jun 1, 1992·Cardiovascular Drugs and Therapy·L M Van Bortel, M A van Baak
Dec 1, 1992·Arteriosclerosis and Thrombosis : a Journal of Vascular Biology·K R FeingoldR M Krauss
Jul 18, 1991·The New England Journal of Medicine·S P HelmrichR S Paffenbarger
Jan 2, 1989·European Journal of Pharmacology·W J JanssensP A Janssen
Aug 1, 1993·Journal of Cardiovascular Pharmacology·M GoldsteinR J Kahn
Sep 1, 1994·British Journal of Clinical Pharmacology·A J BowmanG A Ford
Dec 1, 1994·QJM : Monthly Journal of the Association of Physicians·I RajmanM Kendall
Jun 1, 1994·Journal of Computer-aided Molecular Design·A R Leach, S R Kilvington
Dec 15, 1994·Annals of Internal Medicine·T V PernegerM J Klag
Feb 17, 1999·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·M MangrellaF Rossi
Apr 21, 1999·QJM : Monthly Journal of the Association of Physicians·S L NuttallU Martin
Aug 13, 1999·Progress in Cardiovascular Diseases·C B Guzmán, J R Sowers
Aug 18, 1999·Journal of the Royal Society of Medicine·S Moncada
Nov 11, 1999·Current Opinion in Lipidology·M EvansA Rees
Feb 20, 2004·Journal of Human Hypertension·B WilliamsUNKNOWN British Hypertension Society
Sep 29, 2004·Diabetes Care·Wolfgang Rathmann, Guido Giani

❮ Previous
Next ❯

Citations

Oct 22, 2013·Colloids and Surfaces. B, Biointerfaces·Utpal JanaGuru Prasad Mohanta
Jan 14, 2010·Current Medical Research and Opinion·Vivian A Fonseca
Apr 17, 2008·Journal of Diabetes and Its Complications·Dimitrios Z MytasIoannis A Kyriazis
Dec 8, 2007·Cardiology Clinics·Ragavendra R Baliga
Apr 5, 2013·The Journal of Clinical Hypertension·Prakash DeedwaniaLillian Brener
Jul 17, 2007·The American Journal of Cardiology·William C RobertsDestry J Sulkes
Apr 23, 2015·Current Cardiology Reports·Icilma V FergusKeith C Ferdinand
Jun 11, 2008·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·Charnelda L Gray, Uche A Ndefo
May 18, 2016·Acta Pharmacologica Sinica·Lei ShengHong-Rong Xu
Mar 12, 2017·Current Hypertension Reports·Maria MarketouPanos Vardas
Apr 28, 2009·Clinical Therapeutics·Judy W M Cheng

❮ Previous
Next ❯

Related Concepts

Related Feeds

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.

Adrenergic Receptors: Trafficking

Adrenergic receptor trafficking is an active physiological process where adrenergic receptors are relocated from one region of the cell to another or from one type of cell to another. Discover the latest research on adrenergic receptor trafficking here.

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.